D. Saenz

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML

P. Qiu, K. Rajapakshe, C. Coarfa, 2018, Leukemia.

NEW INSIGHTS INTO CLINICAL TRIAL FOR COLOSTRININ TM IN ALZHEIMER ’ S DISEASE

I. Boldogh, P. Szaniszlo, P. Germán, 2008 .

RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1.

Michael R. Green, K. Rajapakshe, C. Coarfa, 2019, Blood.

Effect of Probiotics (Saccharomyces boulardii) on Microbial Translocation and Inflammation in HIV-Treated Patients: A Double-Blind, Randomized, Placebo-Controlled Trial

J. Horcajada, L. Sorlí, R. Güerri-Fernández, 2015, Journal of acquired immune deficiency syndromes.

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

K. Rajapakshe, C. Coarfa, M. Konopleva, 2019, Blood Cancer Journal.

Effects of Colostrinin on gene expression-transcriptomal network analysis.

I. Boldogh, M. Kruzel, Mitchell W Woodberry, 2009, International immunopharmacology.

New insights into clinical trial for colostrinin™ in Alzheimer’s disease

I. Boldogh, P. Szaniszlo, P. Germán, 2009, The journal of nutrition, health & aging.

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

K. Rajapakshe, C. Coarfa, M. Konopleva, 2019, Blood Cancer Journal.

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML

P. Qiu, K. Rajapakshe, C. Coarfa, 2018, Leukemia.